Infrared emission film, infrared assembly comprising infrared emission film, infrared emission device comprising infrared emission film and application of infrared emission film

Through the flexible infrared ray emitted by the flexible infrared emitting membrane, the problems of high cost, high complexity and low response rate in wound healing and neurological diseases are solved, the wound healing accelerated and nerve factor improvement is achieved, and the inflammatory factors are reduced, and a A safe and convenient treatment method.

CN119055962APending Publication Date: 2024-12-03TAN KAH KEE INNOVATION LAB
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310652786.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the prior art, wound healing and neurological disease treatment have problems such as high cost, complex equipment, difficult operation and low response rate, and traditional drug treatment has side effects and limitations on usage scenarios.

Method used

Using a flexible infrared emitting film, prepared by carbon-based conductive ink, emits infrared rays in the range of 1-200μm, and the temperature is controlled at 35-45℃. It is used to promote wound healing and treatment of neurological diseases, reducing equipment complexity and operation difficulty.

Benefits of technology

It has achieved accelerated wound healing, increased neural factor expression and reduced inflammatory factors, providing a safe, convenient and non-invasive treatment method, reducing treatment costs and operational complexity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055962A_ABST
    Figure CN119055962A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biotechnology and medical instruments, and discloses an infrared emission film, an infrared assembly comprising the infrared emission film, an infrared emission device comprising the infrared emission film and application of the infrared emission film. The infrared emission film is prepared from the carbon-based conductive ink, and has the effects of improving the expression level of cell growth factors, promoting the expression level of neural factors and reducing the expression level of inflammatory factors. According to the invention, the infrared light emitted by the infrared emission film can be used for treating skin wounds, and also can be used for treating nervous system diseases such as depression and the like. The device has the advantages of being simple in structure, small in size and low in cost, the operation difficulty in the treatment process is reduced, and the treatment method is safer and more convenient. In addition, the method provided by the invention is a physical therapy method, and is not limited by use scenes and the like in the aspect of drug therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an infrared emitting film, an infrared component and an infrared emitting device containing the same and applications thereof, and belongs to the field of biotechnology and medical equipment. Background Art

[0002] The skin primarily serves as a shield against the environment. Injury, disease or surgery can lead to loss of integrity of large parts of the skin and severe disturbances in the barrier function. Delayed wound healing and surgical wound dehiscence are important clinical problems, and wound care is an important factor in the clinical setting.

[0003] Wound healing refers to a series of pathological and physiological processes in which local tissues are repaired through regeneration, repair, and reconstruction after tissue loss caused by the action of injury factors. In essence, it is an inherent defensive adaptive response of the body to tissue cell damage caused by various harmful factors. This regeneration and repair is manifested in the restoration of lost tissue structure and can also restore its function to varying degrees.

[0004] Although there are many treatment measures for wounds, almost every one of them has its own limitations. Helium-neon laser therapy mainly dilates blood vessels, promotes blood circulation and removes blood stasis, and relieves inflammation and pain. However, laser therapy is expensive and costly. Helium-neon lasers and other devices are too complex and large in size, making them difficult and unsafe to operate. In addition, although drug therapy can also promote wound healing, traditional drug treatment methods have disadvantages such as limited use scenarios, slow response, and dependence.

[0005] Different neurokines work together to maintain the proliferation, differentiation, survival and regeneration of brain neurons, and play a vital role in the nervous system. The occurrence of nervous system diseases is mainly related to the reduction of neurokines in the brain. Different neurokines in the brain play a decisive role in the growth and development of the brain. The reduction of certain neurokines will cause related diseases. Therefore, these neurokines are closely related to the treatment of nervous system diseases.

[0006] Brain-derived neurotrophic factor (BDNF) is a protein with neurotrophic effects. BDNF and its receptors are widely expressed in the nervous system, distributed in a wide range of areas such as the central nervous system, peripheral nervous system, endocrine system, bone and cartilage tissue, and are mainly expressed in the central nervous system, with the highest content in the hippocampus and cortex. Nerve growth factor (NGF) can promote the growth, development, differentiation and maturation of central and peripheral neurons, maintain the normal function of the nervous system, and accelerate the repair of the nervous system after damage. NGF is widely distributed in various tissues and organs of the body (including the brain), and is the most important type in the nerve growth factor family. It mainly exists in the form of precursors in tissues. γ-Aminobutyric acid (GABA) is an amino acid that is widely present in vertebrates, plants and microorganisms. It is an important inhibitory neurotransmitter of the central nervous system. It has many physiological functions, such as activating glucose metabolism in the brain, promoting acetylcholine synthesis, lowering blood ammonia, anticonvulsant, lowering blood pressure, improving brain function, calming the mind, and promoting growth hormone secretion.

[0007] Neurokines can play a therapeutic role in different nervous system diseases, such as Alzheimer's disease, Parkinson's disease, depression, mental illness, learning and memory diseases, etc. At present, most of these diseases are treated with drugs or surgery: using craniotomy to observe and treat cerebrovascular diseases; taking 10% potassium chloride solution to treat periodic paralysis; using drugs such as fluoxetine to treat depression, etc.

[0008] Inflammatory pain is characterized by hyperalgesia and abnormal pain. Its formation is closely related to the neuroimmune response mediated by inflammatory mediators and inflammatory factors, and can cause anxiety, depression, and cognitive memory impairment. The mechanism by which inflammatory pain leads to spatial memory impairment is complex and may involve disorders of the endocrine system and the immune system. The release of peripheral inflammatory factors mediates central inflammatory responses through multiple mechanisms, among which IL-1β, IL-6, and TNF-α are believed to play an important role.

[0009] Inflammatory cytokines are important mediators of peripheral inflammation and immune responses. Inflammatory cytokines are produced in the periphery and act systemically to induce the growth and differentiation of cells in the immune and hematopoietic systems, and to induce and coordinate the different elements of the acute phase response. Inflammatory cytokines are also produced in the central nervous system and may play an important role in a variety of central nervous system functions. Inflammatory cytokines may also be the cause of neuropathological diseases. Elevated levels of inflammatory cytokines in the central nervous system are seen in a variety of neurological diseases, including AIDS dementia, Alzheimer's disease, multiple sclerosis, systemic lupus erythematosus, central nervous system trauma, and viral and bacterial meningitis.

[0010] Many forms of neuromodulation have been used to regulate brain function and treat brain disorders, and can effectively reduce the level of inflammatory factors in the hippocampus of the brain. Some physical methods, such as electrical, magnetic, and light stimulation, can be used to control neural spike activity, thereby achieving regulation of inflammatory factor levels. Although these methods can effectively reduce the level of inflammatory factors in the brain, the use of this method requires direct contact with the skin during treatment, which increases the danger of the treatment process.

[0011] At present, although there are many treatment measures for neurological diseases, the response rate of neurological disease treatment is still low. Existing drug treatments are limited by their side effects, slow response, poor treatment effects, etc., and it is difficult to completely cure neurological diseases.

[0012] In summary, there is an urgent need to develop a new method for promoting wound healing and to develop a convenient and low-cost instrument for promoting wound healing. In addition, there is also an urgent need to find a new treatment method that has a positive impact on the nervous system and to develop a convenient and low-cost instrument for treating nervous system diseases. Summary of the invention

[0013] In view of the above technical problems, the present invention provides an infrared emitting film 11, which is a flexible film. The wavelength of the infrared ray emitted by the infrared emitting film 11 is 1-200 μm, and the heating temperature of the infrared emitting film 11 is 35-45°C.

[0014] In a preferred embodiment of the present invention, the infrared emitting film 11 is made of carbon-based conductive ink.

[0015] In a preferred embodiment of the present invention, the wavelength of the infrared ray emitted by the infrared emitting film 11 is 1-25 μm, and the heating temperature of the infrared emitting film 11 is 39-43° C.

[0016] In a further preferred embodiment of the present invention, the wavelength of the infrared ray emitted by the infrared emitting film 11 is 5-15 μm, and the heating temperature of the infrared emitting film 11 is 40-42° C.

[0017] Another aspect of the present invention provides a method for preparing the infrared emitting film 11 of the present invention, which comprises the following steps:

[0018] 1. Prepare carbon-based conductive ink precursor dispersion;

[0019] 2. Preparation of carbon-based conductive ink;

[0020] 3. Prepare infrared emitting film.

[0021] In a preferred embodiment of the present invention, the above step 1 comprises:

[0022] Grind the expanded graphite 100-1000 times to a D50 of 200 μm;

[0023] The crushed expanded graphite and conductive carbon black are used as a conductive agent in a mass ratio of (6-10):1;

[0024] The following substances form a mixed solvent in the following mass ratio:

[0025] - Conductive agent 5-20wt%;

[0026] - acrylic resin 20-30wt%;

[0027] - Rheological additive castor oil, the amount of which is 3-6wt% of the amount of the conductive agent;

[0028] -Silane coupling agent, the amount of which is 0.5-2wt% of the amount of the conductive agent;

[0029] - A mixed solvent consisting of terpineol and ethanol in a mass ratio of 3:7, and the remainder;

[0030] The above substances are mixed and stirred to obtain a uniform and foam-free carbon-based conductive ink precursor dispersion.

[0031] In a more preferred embodiment of the present invention, the above step 1 comprises:

[0032] Grind the expanded graphite 450 times to a D50 of 200 μm;

[0033] The crushed expanded graphite and conductive carbon black are used as a conductive agent in a mass ratio of 8:1;

[0034] The following substances form a mixed solvent in the following mass ratio:

[0035] - Conductive agent 10wt%;

[0036] - acrylic resin 25 wt%;

[0037] - Rheological additive castor oil, the amount used is 5wt% of the amount of conductive agent;

[0038] - Silane coupling agent, the amount of which is 1wt% of the amount of the conductive agent;

[0039] - A mixed solvent consisting of terpineol and ethanol in a mass ratio of 3:7, and the remainder.

[0040] The above substances are mixed, and the mixture is stirred for more than 10 minutes using a high-speed stirrer to obtain a uniform and non-foaming carbon-based conductive ink precursor dispersion.

[0041] In a preferred embodiment of the present invention, step 2 comprises:

[0042] The carbon-based conductive ink precursor dispersion prepared in step 1 is ball-milled to a fineness of less than 20 μm, and the viscosity is adjusted to 1000-13000 mPa·s to prepare a carbon-based conductive ink.

[0043] In a preferred embodiment of the present invention, step 3 comprises:

[0044] The carbon-based conductive ink prepared in step 2 is applied on the supporting substrate 10 to obtain a wet film by gravure printing, screen printing or coating, and then dried and cured at low temperature to obtain the infrared emitting film 11 .

[0045] Another aspect of the present invention provides an infrared component, which includes the infrared emitting film 11 of the present invention, electrodes 12 electrically connected to the infrared emitting film 11 , and external wires 13 connected to the electrodes 12 .

[0046] In a preferred embodiment of the present invention, the infrared component is covered with the infrared emitting film 11 described in the present invention on all sides.

[0047] In a preferred embodiment of the present invention, after the infrared component is powered on, it can emit infrared light with a temperature of 35-45°C and a wavelength of 1-200μm, more preferably, it can emit infrared light with a temperature of 39-43°C and a wavelength of 1-25μm, and even more preferably, it can emit infrared light with a temperature of 40-42°C and a wavelength of 5-15μm.

[0048] In a preferred embodiment of the present invention, the electrode 12 and the external lead 13 may be an integrated structure or an independent structure.

[0049] In a preferred embodiment of the present invention, the infrared component further comprises a carrier substrate 10 , and the infrared emitting film 11 is at least partially disposed on the surface of the carrier substrate 10 .

[0050] In a preferred embodiment of the present invention, the supporting substrate 10 is a flexible film, preferably PI, PET, etc., or a hard sheet structure, preferably a glass sheet, a mica sheet or a ceramic sheet, etc.

[0051] In a preferred embodiment of the present invention, the infrared component further comprises an infrared reflective film 16, which is disposed on a surface of the supporting substrate 10 away from the infrared emitting film 11, and is used to reflect infrared rays emitted by the infrared emitting film 11 in the same direction.

[0052] In a preferred embodiment of the present invention, the infrared component further comprises a temperature sensor 15 , which is disposed between the infrared emitting film 11 and the supporting substrate 10 and is used to obtain the heating temperature of the infrared emitting film 11 .

[0053] The present invention can obtain the temperature of the infrared emission film 11 in real time through the temperature sensor 15, accurately control the temperature, and prevent overheating and scalding the skin.

[0054] In a preferred embodiment of the present invention, the infrared component further comprises a gauze 14, which covers the surface of the infrared emitting film 11 away from the supporting substrate 10, so as to avoid direct contact between graphite and skin during treatment.

[0055] In a preferred embodiment of the present invention, the infrared component further comprises an external connector or an external interface 17 connected to the external wire 13 for connecting to an external controller.

[0056] In a preferred embodiment of the present invention, the external connector or external interface 17 is embedded in the carrier substrate 10 and partially exposed to prevent damage.

[0057] On the other hand, the present invention provides an infrared emitting device comprising the infrared emitting film 11 or the infrared component described in the present invention, which further comprises an external controller connected to the external wire 13, and is used to control the infrared emitting film 11 to emit infrared rays, and make the heating temperature reach 35-45°C, preferably make the heating temperature reach 39-43°C, and more preferably make the heating temperature reach 40-42°C.

[0058] In a preferred embodiment of the present invention, the external controller is used to control the infrared emitting film 11 to emit infrared rays for 30-60 minutes each time, more preferably 45 minutes each time.

[0059] On the other hand, the present invention provides the use of the infrared emitting film 11, infrared component or infrared emitting device of the present invention in improving the expression level of cell growth factors, promoting the expression level of neural factors, or reducing the expression level of inflammatory factors. The cell growth factor is preferably TGF-β1, the neural factor is preferably GABA, BDNF and NGF, and the inflammatory factor is preferably IL-6, IL-1β and TNF-α.

[0060] Beneficial Effects

[0061] The present invention uses infrared light emitted by an infrared emitting film to treat the wound surface. Compared with equipment such as helium-neon lasers, this method reduces its cost, and the equipment has a simple structure and a small size, which reduces the difficulty of operation during the treatment process. It is a safer and more convenient treatment method.

[0062] After treatment by the method of the present invention, the expression level of the cell growth factor TGF-β1 can be increased, objectively promoting the proliferation and differentiation of cells in the wound surface, demonstrating the effectiveness of the treatment.

[0063] The present invention uses infrared light emitted by an infrared emitting film to treat nervous system diseases, such as depression, and adopts a non-invasive, non-contact treatment method, which reduces the difficulty of operation during the treatment process and is a safer treatment method.

[0064] After treatment by the method of the present invention, the content of brain nerve factors GABA, BDNF and NGF can be increased, which has a certain improvement effect on the disease, and realizes a non-invasive and medication-free treatment method.

[0065] The present invention uses infrared light emitted by an infrared emitting film to treat depression caused by high levels of inflammatory factors, avoiding the disadvantage of direct contact with the human body in the transcranial magnetic stimulation treatment method, adopts a non-invasive and non-contact method for treatment, reduces the difficulty of operation during the treatment process, and is a safer treatment method.

[0066] After treatment with the method of the present invention, the levels of neuroinflammatory factors IL-6, IL-1β and TNF-α in the brain can be reduced, objectively demonstrating the effectiveness of the treatment.

[0067] In addition, the method of the present invention is a physical therapy and is not subject to restrictions such as usage scenarios in drug therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] Figure 1 It is a schematic diagram of the structure of the infrared component of the present invention;

[0069] 10: supporting substrate; 11: infrared emitting film; 12: electrode; 13: external wire; 15: temperature sensor; 17: external connector.

[0070] Figure 2 It is another schematic diagram of the structure of the infrared component of the present invention;

[0071] 10: supporting substrate; 12: electrode; 14: gauze; 16: infrared reflective film.

[0072] Figure 3 It is the far infrared spectrum emitted by the infrared emitting film of the present invention;

[0073] The wavelengths in the spectrum mainly range from 5-15μm, accounting for more than 80%, which is very close to the range of normal human radiation, simulating the infrared rays emitted by the human body.

[0074] Figure 4 is the wound healing result of mice in each group after treatment;

[0075] Model: model group; FIR: far infrared therapy group; Metal: metal wire control group.

[0076] Figure 5 is a bar graph of the wound area of ​​mice in each group after treatment;

[0077] Model: model group; Graphene Heating: far-infrared treatment group; Metal Heating: metal wire control group.

[0078] Figure 6 It is a bar graph of the cell growth factor content in the serum of the experimental subjects in different treatment groups;

[0079] Model: model group;

[0080] FIR-45: infrared emission film treatment for 45 minutes; FIR-30: infrared emission film treatment for 30 minutes;

[0081] MW-45: metal alloy film treatment for 45 minutes; MW-30: metal alloy film treatment for 30 minutes.

[0082] Figure 7 This is a graph showing the percentage of time that mice in different groups spent in a static state in the tail suspension test;

[0083] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0084] Figure 8 This is a graph showing the percentage of time that mice in different groups spent in a static state in the forced swimming test;

[0085] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0086] Fig. 9 This is a graph showing the percentage of time spent in the open arm by mice in different groups in the high cross test;

[0087] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0088] Fig.10This is a graph showing the ratio of the distance walked on the open arm to the total arm length in the high cross test for mice in different groups;

[0089] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0090] Fig.11 This is a comparison of GABA content between different groups;

[0091] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0092] Fig.12 This is a comparison of BDNF content between different groups;

[0093] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0094] Fig.13 It is a comparison chart of NGF content between different groups;

[0095] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0096] Fig.14 It is a comparison chart of IL-6 content between different groups;

[0097] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0098] Fig.15 is a comparison of IL-1β content between different groups;

[0099] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group.

[0100] Fig.16 is a comparison chart of TNF-α content between different groups;

[0101] Ctrl: blank group; FIR treatment: far infrared treatment group; Stress: depression model group. DETAILED DESCRIPTION

[0102] The present application is further described in detail below through the accompanying drawings and embodiments. Through these descriptions, the characteristics and advantages of the present application will become clearer and more specific.

[0103] The word "exemplary" is used exclusively herein to mean "serving as an example, embodiment, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments. Although various aspects of the embodiments are shown in the drawings, the drawings are not necessarily drawn to scale unless otherwise noted.

[0104] In addition, the technical features involved in different embodiments of the present application described below can be combined with each other as long as they do not conflict with each other.

[0105] Example 1 Preparation of infrared emitting film

[0106] 1. Preparation of carbon-based conductive ink precursor dispersion

[0107] Grind the expanded graphite 100 times to a D50 of 200 μm;

[0108] The crushed expanded graphite and conductive carbon black are used to form a conductive agent in a mass ratio of 6:1;

[0109] The following substances form a mixed solvent in the following mass ratio:

[0110] - Conductive agent 5wt%;

[0111] - acrylic resin 20wt%;

[0112] - Rheological additive castor oil, the amount used is 3wt% of the conductive agent;

[0113] - Silane coupling agent, the amount used is 0.5wt% of the amount of conductive agent;

[0114] - A mixed solvent consisting of terpineol and ethanol in a mass ratio of 3:7, and the remainder.

[0115] The above substances are mixed to obtain a mixture, and the mixture is stirred with a high-speed stirrer for more than 10 minutes to obtain a uniform and non-foaming carbon-based conductive ink precursor dispersion.

[0116] 2. Preparation of carbon-based conductive ink

[0117] The carbon-based conductive ink precursor dispersion prepared above was ball-milled to a fineness of less than 20 μm, and the viscosity was adjusted to 1000 mPa·s according to different printing methods to obtain a carbon-based conductive ink.

[0118] 3. Preparation of infrared emitting film

[0119] The carbon-based conductive ink prepared above is coated on the supporting substrate 10 to obtain a wet film by gravure printing, screen printing, coating, etc., and then dried and cured at low temperature (120° C.) to obtain the infrared emitting film 11 .

[0120] Example 2 Preparation of infrared emitting film

[0121] 1. Preparation of carbon-based conductive ink precursor dispersion

[0122] Grind the expanded graphite 450 times to a D50 of 200 μm;

[0123] The crushed expanded graphite and conductive carbon black are used as a conductive agent in a mass ratio of 8:1;

[0124] The following substances form a mixed solvent in the following mass ratio:

[0125] - Conductive agent 10wt%;

[0126] - acrylic resin 25 wt%;

[0127] - Rheological additive castor oil, the amount used is 5wt% of the amount of conductive agent;

[0128] - Silane coupling agent, the amount of which is 1wt% of the amount of the conductive agent;

[0129] - A mixed solvent consisting of terpineol and ethanol in a mass ratio of 3:7, and the remainder.

[0130] The above substances are mixed to obtain a mixture, and the mixture is stirred with a high-speed stirrer for more than 10 minutes to obtain a uniform and non-foaming carbon-based conductive ink precursor dispersion.

[0131] 2. Preparation of carbon-based conductive ink

[0132] The carbon-based conductive ink precursor dispersion prepared above was ball-milled to a fineness of less than 20 μm, and the viscosity was adjusted to 6000 mPa·s according to different printing methods to obtain a carbon-based conductive ink.

[0133] 3. Preparation of infrared emitting film

[0134] The carbon-based conductive ink prepared above is coated on the supporting substrate 10 to obtain a wet film, which is then dried and cured at a low temperature (150° C.) to obtain the infrared emitting film 11 .

[0135] Figure 3 This is the far infrared spectrum released by the infrared emitting film 11 prepared in this embodiment. Figure 3 As shown, the infrared emitting film 11 prepared in this embodiment has a wavelength mainly in the range of 5-15 μm (accounting for more than 80%), which is very close to the range of normal human body radiation (ie, simulating the infrared emission of the human body).

[0136] Example 3 Preparation of infrared emitting film

[0137] 1. Preparation of carbon-based conductive ink precursor dispersion

[0138] Grind the expanded graphite 1000 times to a D50 of 200 μm;

[0139] The crushed expanded graphite and conductive carbon black are used to form a conductive agent in a mass ratio of 10:1;

[0140] The following substances form a mixed solvent in the following mass ratio:

[0141] - Conductive agent 20wt%;

[0142] - acrylic resin 30wt%;

[0143] - Rheological additive castor oil, the amount used is 6wt% of the amount of conductive agent;

[0144] - Silane coupling agent, the amount used is 2wt% of the conductive agent;

[0145] - A mixed solvent consisting of terpineol and ethanol in a mass ratio of 3:7, and the remainder.

[0146] The above substances are mixed to obtain a mixture, and the mixture is stirred with a high-speed stirrer for more than 10 minutes to obtain a uniform and non-foaming carbon-based conductive ink precursor dispersion.

[0147] 2. Preparation of carbon-based conductive ink

[0148] The carbon-based conductive ink precursor dispersion prepared above was ball-milled to a fineness of less than 20 μm, and the viscosity was adjusted to 13000 mPa·s according to different printing methods to obtain a carbon-based conductive ink.

[0149] 3. Preparation of infrared emitting film

[0150] The carbon-based conductive ink prepared above is coated on the supporting substrate 10 to obtain a wet film by gravure printing, screen printing, coating, etc., and then dried and cured at low temperature (200° C.) to obtain the infrared emitting film 11 .

[0151] Example 4 Preparation of infrared components and infrared devices

[0152] like Figure 1 and Figure 2 As shown, the infrared emitting film 11 of the present invention can also be prepared into an infrared component, which includes the infrared emitting film 11 prepared in Example 1, Example 2 or Example 3 of the present invention, electrodes 12 electrically connected to the infrared emitting film 11, and external wires 13 connected to the electrodes 12.

[0153] Furthermore, the infrared component of the present invention may include a carrier substrate 10, and the infrared emitting film 11 is at least partially disposed on the surface of the carrier substrate 10. The carrier substrate 10 is a flexible film such as PI, PET, or a hard sheet structure such as a glass sheet, mica sheet or ceramic sheet.

[0154] Furthermore, the infrared component of the present invention may include an infrared reflective film 16 disposed on a surface of the carrier substrate 10 away from the infrared emitting film 11 , for reflecting infrared rays emitted by the infrared emitting film 11 in the same direction.

[0155] Furthermore, the infrared component of the present invention may include a temperature sensor 15, which is disposed between the infrared emitting film 11 and the supporting substrate 10, and is used to obtain the heating temperature of the infrared emitting film 11. The temperature of the infrared emitting film 11 can be obtained in real time through the temperature sensor 15, the temperature can be accurately controlled, and overheating and scalding of the skin can be prevented.

[0156] Furthermore, the infrared component of the present invention may include gauze 14 covering the surface of the infrared emitting film 11 away from the supporting substrate 10, so as to avoid direct contact between graphite and skin during treatment.

[0157] The embodiment of the present invention further provides an infrared emitting device, which may include Figure 1 The infrared emission component shown or Figure 2 Infrared emission assembly shown. In addition, the infrared emission device also includes an external controller. The external controller is connected to the external wire 13 and is used to control the infrared emission film 11 to emit infrared rays. The controller can control the external power supply to supply power to the electrode 12 through the external wire 13 so that it heats the infrared emission film 11. At this time, the controller can be equivalent to a control switch, and the controller controls the conduction and disconnection of the external power supply and the electrode 12 to achieve the control of the infrared emission film 11 to emit infrared rays.

[0158] Further, the controller can also be used to control the temperature of the infrared emitting film 11, and the heating temperature of the infrared emitting film 11 can be controlled to be heated to 35°C to 45°C, such as 35°C, 39°C, 40°C, 42°C, 43°C, 45°C, etc. More specifically, the heating temperature of the infrared emitting film 11 is controlled to be heated to 39°C to 43°C, 40°C-42°C, such as 39°C, 40°C, 42°C, 43°C, etc.

[0159] Furthermore, when the controller specifically controls the temperature of the infrared emission film 11, it can control the temperature of the infrared emission film 11 detected by the temperature sensor 15. Specifically, the controller is connected to the temperature sensor 15 by signal. The controller can receive the temperature signal of the infrared emission film 11 fed back by the temperature sensor 15, and control the temperature of the infrared emission film 11 according to the temperature signal. For example, if the heating temperature of the infrared emission film 11 is 40°C, when the temperature signal fed back by the temperature sensor 15 is lower than 40°C, the controller controls the infrared emission film 11 to continue to be heated; when the temperature signal fed back by the temperature sensor 15 reaches 40°C, the controller controls to stop heating the infrared emission film 11. It should be understood that the above-mentioned controller can be a common control device such as a PLC, a single-chip microcomputer or an industrial computer, and it is a common control logic for the controller to control the heating temperature of the infrared emission film 11 according to the temperature signal, so it will not be described in detail here.

[0160] Furthermore, the controller is also used to control the time when the infrared emitting film 11 emits infrared rays. For example, the emission time can be 30-60 minutes each time, such as 30 minutes, 40 minutes, 45 minutes, 50 minutes, 60 minutes, and other different times. When specifically controlling the emission time of the infrared emitting film 11, it can be controlled by a timer inside the controller or by a program. The above timer and time control program are conventional time control methods and will not be described in detail here.

[0161] Furthermore, the infrared component of the present invention may include an external connector or an external interface 17 connected to the external wire 13 for connecting to an external controller.

[0162] In other embodiments, the external connector or external interface 17 is buried in the carrier substrate and partially exposed to prevent damage.

[0163] In the description of the present application, it should be noted that the terms "upper", "lower", "inside", "outside", "front", "back", "left", "right", etc. indicate directions or positional relationships based on the directions or positional relationships in the working state of the present application. They are only for the convenience of describing the present application and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific direction, be constructed and operated in a specific direction. Therefore, they should not be understood as limitations on the present application.

[0164] In the description of this application, it should be noted that, unless otherwise clearly specified and limited, the terms "install", "connect" and "connect" should be understood in a broad sense. For ordinary technicians in this field, the specific meanings of the above terms in this application can be understood according to specific circumstances.

[0165] Example 5 Animal experiment on promoting the expression of cell growth factors

[0166] 1. Establishment of mouse model

[0167] Several SPF-grade healthy female C57BL / 6 mice weighing 18-22 g were purchased from the Experimental Animal Center of Xiamen University and divided into a model group, a metal wire control group, and a far-infrared treatment group.

[0168] First, the mouse back was depilated, and a wound of 10×10 mm was cut on the mouse back using medical scissors to create a model for the mouse.

[0169] 2. Treatment of mice

[0170] The mice were then treated.

[0171] The infrared emitting film 11 prepared in Example 2 with a size of 15×15 mm was pasted on the back wounds of mice in the treatment group, and the mice were placed in an infrared environment and treated at 43° C. for 45 minutes every day.

[0172] The wire control group had a 15×15 mm wire film applied to the back wound and was treated at 43°C for 45 min every day.

[0173] After each treatment, the wound area of ​​the mouse was traced with a pen and transparent paper, and the size of the wound was calculated using computer software ImageJ.

[0174] 3. Determination of the content of cell growth factor (TGF-β1) in experimental mice

[0175] Orbital blood was collected from mice in different groups, allowed to stand for 1 hour, and then centrifuged at -4°C and 11,000 r / min for 15 min. 50 μL of the supernatant was taken and the TGF-β1 concentration was measured using an Elisa kit (Wuhan Saipei Biotechnology Co., Ltd., Mouse TGF-β1 Elisa Kit). The Elisa detection process was carried out according to the instructions in the kit manual, and the final absorbance value was converted into the content of cell growth factor (TGF-β1) in serum.

[0176] 4. Results Analysis

[0177] The wound areas of different groups were compared. The results showed that the wound healing of mice treated with infrared emission film was significantly accelerated. Figure 4 and Figure 5 shown.

[0178] The contents of mouse cell growth factor (TGF-β1) were compared between different groups. The results showed that the concentration of cell growth factor in the serum of mice treated with the infrared emission film of the present invention (FIR group) was significantly increased, which was beneficial to the wound healing of mice. The specific results are as follows: Figure 6 shown.

[0179] In summary, the infrared emitting film 11 of the present invention can significantly promote wound healing and increase the level of cell growth factor expression, thereby achieving the effect of accelerating the wound healing rate.

[0180] Example 6 Animal experiment on promoting the expression of neural factors and reducing the expression of inflammatory factors

[0181] 1. Establishment of mouse model

[0182] Several SPF-grade healthy female C57BL / 6 mice, weighing 18-22 g, were purchased from the Experimental Animal Center of Xiamen University and divided into a blank group, a depression model group, and a far-infrared treatment group.

[0183] Chronic stress was used to create a model for mice. The mice were placed in a 50mL centrifuge tube and kept under stress for 2 hours every day. The model was successfully established after one month.

[0184] 2. Treatment of mice

[0185] The mice were then treated.

[0186] The mice in the treatment group were placed in the infrared device prepared in Example 4, so that the mice were in an infrared environment and treated at 40° C. for 1 hour every day.

[0187] The blank group and depression model group served as controls and received no treatment.

[0188] 3. Behavioral testing of experimental mice

[0189] During the treatment, mice were subjected to behavioral tests of high cross, tail suspension, and forced swimming every week.

[0190] High cross test: the wall is 5 cm wide, the arm is 35 cm long, the wall is 15 cm high, and the cross is 50 cm from the ground. The CleverSys TopScanLite system is used to analyze the experimental results of mice within 5 minutes. The proportion of time the mice stay in the open arm and the proportion of the distance the mice walk on the open arm to the total arm length in the high cross test are recorded to represent the anxiety of the mice.

[0191] Tail suspension test: Wrap the mouse’s tail with a medical bandage and hang it upside down at an appropriate distance. The experiment lasts for 6 minutes. The CleverSys TopScanLite system is used to analyze the mouse’s activity within 4 minutes after the experiment. The proportion of time the mouse is still during the tail suspension test is recorded to characterize the mouse’s state of despair.

[0192] Forced swimming test: The mice were placed in a transparent bucket with a diameter of 10 cm, a height of 35 cm, and a water depth of 25 cm for 6 minutes. The CleverSys TopScanLite system was used to analyze the activity of the mice within 4 minutes after the experiment, and the proportion of time the mice were in a static state during the forced swimming test was recorded to characterize the state of despair of the mice.

[0193] 4. Determination of the levels of neurokines GABA, BDNF and NGF and inflammatory factors IL-6, IL-1β and TNF-α in the hippocampus of experimental mice

[0194] After the treatment, the hippocampal tissues of the mice in each group were taken out and made into tissue homogenates, and the levels of γ-aminobutyric acid (detected by Mouse GABA Elisa Kit, Shanghai Jining Biotechnology Co., Ltd.), brain-derived neurotrophic factor (detected by Mouse BDNF Elisa Kit, Shanghai Jining Biotechnology Co., Ltd.), nerve growth factor (detected by Mouse NGF Elisa Kit, Shanghai Jining Biotechnology Co., Ltd.), interleukin 6 (detected by Mouse IL-6 Elisa Kit, Shanghai Jining Biotechnology Co., Ltd.), interleukin 1β (detected by Mouse IL-1β Elisa Kit, Shanghai Jining Biotechnology Co., Ltd.) and tumor necrosis factor α (detected by Mouse TNF-α Elisa Kit, Shanghai Jining Biotechnology Co., Ltd.) in the hippocampus of each group of mice were detected.

[0195] 5. Results Analysis

[0196] During the treatment, the mice were tested for behavior every week. The results showed that the behavior of the mice treated with the infrared device of the present invention was significantly improved. The specific results are as follows: Figure 7-10 shown.

[0197] The contents of GABA, BDNF and NGF in the hippocampus of mice in different groups were compared. The results showed that after treatment with the infrared device of the present invention, the contents of three neurological factors, GABA, BDNF and NGF, in the hippocampus of mice increased significantly, by 26.87%, 18.39% and 27.90% respectively. The specific results are as follows: Figure 11-13 shown.

[0198] The contents of IL-6, IL-1β and TNF-α in the hippocampus of mice in different groups were compared. The results showed that after treatment with the infrared device of the present invention, the contents of the three inflammatory factors IL-6, IL-1β and TNF-α in the hippocampus of mice were significantly reduced, by 31.17%, 18.13% and 28.50% respectively. The specific results are as follows Figure 14-16 shown.

[0199] In summary, the infrared device of the present invention can significantly increase the content of neural factors in the hippocampus, thereby promoting the regeneration of neurons and maintaining the survival of neurons, thereby achieving the effect of treating depression; and the infrared device of the present invention can also significantly reduce the content of inflammatory factors in the hippocampus, thereby reducing the oxidative stress damage of the hippocampus, thereby achieving the effect of treating depression.

[0200] The present application has been described above in conjunction with preferred embodiments, but these embodiments are only exemplary and serve only as an illustration. On this basis, various replacements and improvements may be made to the present application, all of which fall within the scope of protection of the present application.

Claims

1. An infrared emitting film, which is a flexible film, preferably made of carbon-based conductive ink, the wavelength of the infrared light emitted by it is 1-200 μm, preferably 1-25 μm, more preferably 5-15 μm, and the heating temperature of the infrared emitting film is 35-45°C, preferably 39-43°C, more preferably 40-42°C.

2. A method for preparing the infrared emitting film according to claim 1, comprising the steps of: (1) preparing a carbon-based conductive ink precursor dispersion; (2) preparing carbon-based conductive ink; (3) preparing infrared emitting film; in, Step (1) comprises: Grind the expanded graphite 100-1000 times to a D50 of 200 μm, preferably 450 times; The crushed expanded graphite and conductive carbon black are used as a conductive agent in a mass ratio of (6-10):1, preferably in a mass ratio of 8:1; The following substances form a mixed solvent in the following mass ratio: - Conductive agent 5-20wt%, preferably 10wt%; - acrylic resin 20-30wt%, preferably 25wt%; - rheological agent castor oil, the amount of which is 3-6wt% of the amount of the conductive agent, preferably 5wt%; - Silane coupling agent, the amount of which is 0.5-2wt% of the amount of the conductive agent, preferably 1wt%; - A mixed solvent consisting of terpineol and ethanol in a mass ratio of 3:7, and the remainder; The above substances are mixed and stirred, preferably using a high-speed stirrer to stir the mixture for more than 10 minutes to obtain a uniform and foam-free carbon-based conductive ink precursor dispersion.

3. The method according to claim 2, wherein step (2) comprises: The carbon-based conductive ink precursor dispersion prepared in step (1) is ball-milled to a fineness of less than 20 μm, and the viscosity is adjusted to 1000-13000 mPa·s to obtain a carbon-based conductive ink.

4. The method according to claim 2 or 3, wherein step (3) comprises: The carbon-based conductive ink prepared in step (2) is applied to a supporting substrate by gravure printing, screen printing or coating to obtain a wet film, which is then dried and cured at low temperature to obtain the infrared emitting film, wherein the low temperature is preferably below 200°C. 5 . An infrared component, comprising the infrared emitting film according to claim 1 , electrodes electrically connected to the infrared emitting film, and external wires connected to the electrodes, respectively. 6 . The infrared component according to claim 5 , wherein the infrared emitting film according to claim 1 is covered on all four sides of the component.

7. According to the infrared component of claim 5 or 6, after the infrared component is powered on, it can emit infrared light with a temperature of 35-45°C and a wavelength of 1-200μm, preferably emit infrared light with a temperature of 39-43°C and a wavelength of 1-25μm, and more preferably emit infrared light with a temperature of 40-42°C and a wavelength of 5-15μm. 8 . The infrared component according to claim 5 , wherein the electrode and the external wire are an integrated structure or an independent structure. 9 . The infrared component according to claim 5 , further comprising a carrying substrate, wherein the infrared emitting film is at least partially disposed on a surface of the carrying substrate. 10 . The infrared component according to claim 9 , wherein the supporting substrate is a flexible film, preferably PI, PET, etc., or a hard sheet structure, preferably a glass sheet, a mica sheet, a ceramic sheet, etc.

11. The infrared component according to any one of claims 5 to 10, further comprising an infrared reflective film, which is arranged on a surface of the supporting substrate away from the infrared emitting film, and is used to reflect infrared rays emitted by the infrared emitting film in the same direction. 12 . The infrared component according to claim 5 , further comprising a temperature sensor, which is disposed between the infrared emitting film and the supporting substrate and is used to obtain the heating temperature of the infrared emitting film. 13 . The infrared component according to claim 5 , further comprising gauze covering a surface of the infrared emitting film away from the supporting substrate.

14. The infrared component according to any one of claims 5 to 13, further comprising an external connector or an external interface connected to the external wire for connecting to an external controller, wherein the external connector or the external interface is preferably buried in the carrier substrate and partially exposed.

15. An infrared emitting device comprising the infrared emitting film according to claim 1 or the infrared component according to any one of claims 5 to 14, further comprising an external controller connected to the external wire, for controlling the infrared emitting film to emit infrared rays and making the heating temperature reach 35-45°C, preferably 39-43°C, and more preferably 40-42°C.

16. The device according to claim 15, wherein the external controller is used to control the infrared emitting film to emit infrared rays for 30-60 minutes each time, preferably 45 minutes each time.

17. Use of the infrared emitting film according to claim 1, the infrared component according to any one of claims 5 to 14, or the device according to claim 15 or 16 for increasing the expression level of cell growth factors, promoting the expression level of neural factors, or reducing the expression level of inflammatory factors, wherein the cell growth factor is preferably TGF-β1, the neural factors are preferably GABA, BDNF and NGF, and the inflammatory factors are preferably IL-6, IL-1β and TNF-α.

Citation Information

Patent Citations

  • Infrared device and application thereof

    CN113952622A

  • An infrared ray generator

    KR1020090047734A